Re: my mid year review of GERN
IF.... and that's a HUGE IF, a few of the spinal cord patients treated had significant improvement the stock price would grow exponentially with each reported improvement and be the biggest story in the health care sector. I have NO doubt the FDA would have an almost immediate approval of the product for obvious reasons as opposed to waiting years and years for trial results to come in.
I thought the odds of seeing significant improvement in this patient population was good until the trial dosage was released...... with such low dose one time treatment it significantly lowers the odds of dramatic improvement. In fact I view it as 'cruel and unusual' based on getting patients hopes up only to have them be given a miniscule one time treatment.